Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) CTO Michael Skynner sold 972 shares of the company's stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $22.26, for a total value of $21,636.72. Following the completion of the transaction, the chief technology officer now directly owns 92,945 shares of the company's stock, valued at approximately $2,068,955.70. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Bicycle Therapeutics Stock Up 6.3 %
Shares of NASDAQ BCYC opened at $23.60 on Friday. Bicycle Therapeutics plc has a 12-month low of $12.54 and a 12-month high of $28.20. The firm's 50-day simple moving average is $23.36 and its 200 day simple moving average is $22.93. The company has a quick ratio of 14.77, a current ratio of 14.77 and a debt-to-equity ratio of 0.01. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -5.30 and a beta of 0.90.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.10) by $0.33. Bicycle Therapeutics had a negative net margin of 417.88% and a negative return on equity of 32.80%. The company had revenue of $9.36 million for the quarter, compared to analyst estimates of $6.13 million. Bicycle Therapeutics's revenue was down 17.9% compared to the same quarter last year. On average, research analysts expect that Bicycle Therapeutics plc will post -3.17 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Bicycle Therapeutics
Next opportunity for crypto millions
From Crypto 101 Media | Ad
"Uptober" is here, and it's not just a clever name.
Historically, October ignites crypto's most explosive gains. This year could be off the charts.
Don't let this opportunity pass you by. In crypto, timing is everything.
Go here to discover the #1 crypto set to dominate Uptober.
A number of institutional investors and hedge funds have recently made changes to their positions in BCYC. PNC Financial Services Group Inc. bought a new position in Bicycle Therapeutics in the fourth quarter valued at approximately $137,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Bicycle Therapeutics by 71.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,859 shares of the company's stock worth $171,000 after purchasing an additional 2,858 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Bicycle Therapeutics during the second quarter worth $206,000. PDS Planning Inc acquired a new stake in shares of Bicycle Therapeutics during the first quarter worth $210,000. Finally, Natixis Advisors LLC bought a new stake in Bicycle Therapeutics in the second quarter valued at about $261,000. Institutional investors own 86.15% of the company's stock.
Wall Street Analyst Weigh In
Several research analysts recently commented on the company. JMP Securities reaffirmed a "market outperform" rating and issued a $32.00 target price on shares of Bicycle Therapeutics in a research report on Monday, September 16th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Bicycle Therapeutics in a report on Monday, September 9th. Needham & Company LLC restated a "buy" rating and set a $38.00 target price on shares of Bicycle Therapeutics in a research report on Monday, September 16th. HC Wainwright reiterated a "buy" rating and set a $55.00 price objective on shares of Bicycle Therapeutics in a research note on Monday, September 16th. Finally, Royal Bank of Canada initiated coverage on shares of Bicycle Therapeutics in a research note on Friday, September 6th. They issued an "outperform" rating and a $35.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Bicycle Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $44.56.
Get Our Latest Report on Bicycle Therapeutics
About Bicycle Therapeutics
(
Get Free Report)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
